The two trials, part of the ACTIV-3 master protocol, will test monoclonal antibody therapeutics in hospitalized participants.

Thursday, December 17, 2020 Investigational COVID-19 Therapeutics to be Evaluated in Large Clinical Trials Today, two randomized, controlled Phase 3 trials to test potential therapeutics for COVID-19, supported by NIAID, began enrolling participants. The ACTIV-3 master protocol has begun two sub-studies to test different therapeutics based on monoclonal antibodies. One trial will test a neutralizing monoclonal antibody, VIR-7831, and the other will test a combination of BRII-196 and BRII-198, two neutralizing monoclonal antibodies. The trials will initially enroll participants hospitalized with COVID-19. If the therapeutics appear to be safe and effective after a DSMB has reviewed data from these first participants, the trials will expand to enroll more patients. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107